125 results
424B4
APTO
Aptose Biosciences Inc
26 Jan 24
Prospectus supplement with pricing info
5:30pm
and South Korea. Clinical data from tuspetinib in AML were presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 … , 2023, Aptose featured tuspetinib in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
8-K
EX-99.1
APTO
Aptose Biosciences Inc
11 Dec 23
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
6:30am
myeloid leukemia (R/R AML) in the ongoing APTIVATE Phase 1/2 study. Data were presented in an oral presentation today at the 65th American Society
8-K
EX-99.1
ln47kz0u
9 Nov 23
Aptose Reports Results for the Third Quarter 2023
4:15pm
8-K
EX-99.1
i25zoc
2 Nov 23
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
9:15am
8-K
EX-99.1
b866auq 9sqzudsm
10 Aug 23
Aptose Reports Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
nddj548i8x6qd
8 May 23
Aptose Reports Results for the First Quarter 2023
4:05pm
8-K
EX-99.2
feqwt7
12 Dec 22
Entry into a Material Definitive Agreement
8:00am
8-K
twoii
9 Dec 22
Other Events
6:48pm
8-K
EX-99.1
wcyt1b5nf9ie6afb
7 Dec 22
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
4:15pm
8-K
EX-99.1
y4vq8 k9cgkk
3 Nov 22
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
9:10am